Over the past two years, however, five pharmaceutical companies have committed to set up plants here, which will, at steady state, churn out over a billion doses annually.
The products range from traditional types such as live-attenuated and recombinant vaccines to the latest mRNA ones, with the first output set to be rolled out as early as 2023.